Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
Holding NUVL?
Track your performance easily
NUVL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$41.16 - $113.51
Previous Close$104.75
Volume539.39K
Average Volume (3M)421.87K
Market Cap
$6.79B
Enterprise Value$6.13B
Total Cash (Recent Filing)$657.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 07, 2024EPS Estimate
-$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding64,797,603
10 Day Avg. Volume890,853
30 Day Avg. Volume421,873
Standard Deviation0.27
R-Squared0.06
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)10.66
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-34.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-39.80
Forecast
1Y Price Target
$109.90Price Target Upside7.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Nuvalent News
Bulls Say, Bears Say
Bulls Say
Clinical DataThe data reaffirm NVL-655 as a best-in-class ALK inhibitor.
Enrollment And Development TimelinesThe rapid pace of enrollment in the ongoing Phase 2 studies is striking, as NUVL has enrolled N=227 ROS1 patients in ~1 year as well as N=229 ALK patients in ~7 months.
Market PotentialNUVL continues to demonstrate a clear best-in-class profile, has accelerated development timelines relative to prior guidance.
Bears Say
EarningsNuvalent reported a net loss of $57.2M, which was wider than the consensus estimate of $49.4M.
Financial PerformanceDilutive financing beyond what has been anticipated could negatively impact shareholder value.
Market CompetitionPotential emergence of new competitors poses a significant risk to the company's market position.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $41.16 and its highest was $113.51 in the past 12 months.
What is Nuvalent’s market cap?
Currently, no data Available
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Aug 08, 2024. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.763 by -$0.117.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -$0.94.
How many shares outstanding does Nuvalent have?
Nuvalent has 59,362,350 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.763. Following the earnings report the stock price went up 4.152%.
Which hedge fund is a major shareholder of Nuvalent?
Among the largest hedge funds holding Nuvalent’s share is Deerfield Management Company, LP. It holds Nuvalent’s shares valued at 2B.
---
Nuvalent Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.90 (7.08% Upside)
$109.90 (7.08% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 727.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 41.0%
Last 30 Days ▲ 84.7%
Last 30 Days ▲ 84.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.17%
12-Months-Change
Fundamentals
Return on Equity
-32.81%
Trailing 12-Months
Asset Growth
52.78%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
---
NUVL Stock 12 Month Forecast
Average Price Target
$109.90
▲(7.08% Upside)
Technical Analysis
Best Analysts Covering NUVL
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+43.38%
reiterated a buy rating 10 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +43.38% per trade.
---